Dr. Goldstein on the Fox Chase Breast Evaluation Center

Lori J. Goldstein, MD
Published: Friday, Oct 28, 2011

Lori J. Goldstein, MD, founded the Naomi and Phil Lippincott Breast Evaluation Center (BEC) at Fox Chase Cancer Center over 20 years ago. This multidisciplinary center not only meets the physical demands of cancer patients but also meets their psychosocial needs.

The center employs both social workers and educators that provide education about both the resources available and vocabulary. Not only does the center address the needs of the patients but also the needs of the whole family.

BEC addresses the psychosocial needs of breast cancer patients in multiple ways, it has several clinical psychiatrists on staff, special programs for women with young families, and past patients have donated several items they found useful.

Find out more about the Naomi and Phil Lippincott Breast Evaluation Center.
 
Lori J. Goldstein, MD, founded the Naomi and Phil Lippincott Breast Evaluation Center (BEC) at Fox Chase Cancer Center over 20 years ago. This multidisciplinary center not only meets the physical demands of cancer patients but also meets their psychosocial needs.

The center employs both social workers and educators that provide education about both the resources available and vocabulary. Not only does the center address the needs of the patients but also the needs of the whole family.

BEC addresses the psychosocial needs of breast cancer patients in multiple ways, it has several clinical psychiatrists on staff, special programs for women with young families, and past patients have donated several items they found useful.

Find out more about the Naomi and Phil Lippincott Breast Evaluation Center.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x